Branded Products

green round medication tablets

By identifying unmet needs and applying our API development, manufacturing, and logistics expertise gained from years of excellence in manufacturing, we're uniquely positioned to bring value to the market under our own label.

The addition of Chartwell Labs and Chartwell Actives coupled with an ongoing acquisition plan of strategic industry interest, ensures that the market will be seeing many more valuable branded products from Chartwell in the coming years.

Our Growing Brand

Chartwell's first branded drug, LymePak (doxycycline hyclate tablets), was approved by the FDA in June of 2018.

Learn more about LymePak.
chartwell lymepak for treatment of lyme disease
Chartwell Pharmaceuticals